Author:
Al-Monajjed Rouvier,Serón-Möller Raúl Felipe,Radtke Jan Philipp
Publisher
Springer Science and Business Media LLC
Reference9 articles.
1. Page EC, Bancroft EK, Brook MN et al (2019) Interim results from the IMPACT study: evidence for prostate-specific antigen screening in BRCA2 mutation carriers. Eur Urol 76(6):831–842
2. Raymond VM, Mukherjee B, Wang F et al (2013) Elevated risk of prostate cancer among men with Lynch syndrome. J Clin Oncol 31(14):1713–1718. https://doi.org/10.1200/JCO.2012.44.1238
3. Eldred-Evans D, Burak P, Connor MJ et al (2021) Population-based prostate cancer screening with magnetic resonance imaging or ultrasonography: the IP1-PROSTAGRAM study. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2020.7456
4. Segal N, Margel D (2020) Imaging-based prostate cancer screening among BRCA mutation carriers-results from the first round of screening. Ann Oncol 31(11):1545–1552
5. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF) (2021) S3-Leitlinie Prostatakarzinom, Langversion 6.0, AWMF Registernummer: 043/022OL. http://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom/. Zugegriffen: 12. Febr. 2022